Trial Protocol: Communicating DNA-based risk assessments for Crohn's disease: a randomised controlled trial assessing impact upon stopping smoking

Whitwell, Sophia C. L.; Mathew, Christopher G.; Lewis, Cathryn M.; Forbes, Alastair; Watts, Sally; Sanderson, Jeremy; Hollands, Gareth J.; Prevost, A. Toby; Armstrong, David; Kinmonth, Ann Louise; Sutton, Stephen; Marteau, Theresa M.
January 2011
BMC Public Health;2011, Vol. 11 Issue 1, p44
Academic Journal
Background: Estimates of the risk of developing Crohn's disease (CD) can be made using DNA testing for mutations in the NOD2 (CARD15) gene, family history, and smoking status. Smoking doubles the risk of CD, a risk that is reduced by stopping. CD therefore serves as a timely and novel paradigm within which to assess the utility of predictive genetic testing to motivate behaviour change to reduce the risk of disease. The aim of the study is to describe the impact upon stopping smoking of communicating a risk of developing CD that incorporates DNA analysis. We will test the following main hypothesis: Smokers who are first degree relatives (FDRs) of CD probands are more likely to make smoking cessation attempts following communication of risk estimates of developing CD that incorporate DNA analysis, compared with an equivalent communication that does not incorporate DNA analysis. Methods/design: A parallel groups randomised controlled trial in which smokers who are FDRs of probands with CD are randomly allocated in families to undergo one of two types of assessment of risk for developing CD based on either: i. DNA analysis, family history of CD and smoking status, or ii. Family history of CD and smoking status The primary outcome is stopping smoking for 24 hours or longer in the six months following provision of risk information. The secondary outcomes are seven-day smoking abstinence at one week and six month follow-ups. Randomisation of 470 smoking FDRs of CD probands, with 400 followed up (85%), provides 80% power to detect a difference in the primary outcome of 14% between randomised arms, at the 5% significance level. Discussion: This trial provides one of the strongest tests to date of the impact of communicating DNA-based risk assessment on risk-reducing behaviour change. Specific issues regarding the choice of trial design are discussed. Trial Registration: ISRCTN: ISRCTN21633644.


Related Articles

  • Effect of communicating DNA based risk assessments for Crohn's disease on smoking cessation: randomised controlled trial.  // Inflammatory Bowel Disease Monitor;2012, Vol. 13 Issue 2, p74 

    This randomized controlled study investigated whether prior knowledge of genetic risk for Crohn's disease can influence a modifiable behavioral risk factor, namely smoking, in individuals with a family history of Crohn's disease.

  • Inflammatory Bowel Disease. Abraham, Clara; Cho, Judy H. // New England Journal of Medicine;11/19/2009, Vol. 361 Issue 21, p2066 

    The article offers information on the medical condition known as the inflammatory bowel disease. Several treatment options for this condition are cited such as lifestyle alteration like smoking cessation for those who are suffering from Chron's disease a well as surgical interventions. The...

  • Possible Exacerbation of Crohn's Disease Caused By Varenicline. Rowland, Martin; Koenigsfeld, Carrie Foust; Wall, Geoffrey C. // Journal of Smoking Cessation;Apr2008, Vol. 3 Issue 1, p63 

    Purpose: To report a case of an increase in Crohn's disease (CD) activity possibly caused by varenicline. Background: Smoking cigarettes has been shown to be an independent risk factor for the development of CD and is associated with a more aggressive disease course. Smoking cessation is...

  • A Prospective Study of Cigarette Smoking and the Risk of Inflammatory Bowel Disease in Women. Higuchi, Leslie M; Khalili, Hamed; Chan, Andrew T; Richter, James M; Bousvaros, Athos; Fuchs, Charles S // American Journal of Gastroenterology;Sep2012, Vol. 107 Issue 9, p1399 

    OBJECTIVES:Long-term data on the influence of cigarette smoking, especially cessation, on the risk of Crohn's disease (CD) and ulcerative colitis (UC) are limited.METHODS:We conducted a prospective study of 229,111 women in the Nurses' Health Study (NHS) and Nurses' Health Study II (NHS II)....

  • They're bugs, Jim, but not as we know them.  // Gut;Sep2004, Vol. 53 Issue 9, p1385 

    The article discusses about various bacterial antigens that have been revealed in chronic inflammation in colitis and crohn's disease through pathogenesis. There is a relatively small number of immunodominant antigens that stimulate pathological T cell responses. Specific bacterial antigens...

  • DLG5 Variants in Inflammatory Bowel Disease. B√ľning, Carsten; Geerdts, Lars; Fiedler, Thomas; Gentz, Enno; Pitre, Ghyslaine; Reuter, Wolf; Luck, Werner; Buhner, Sabine; Molnar, Tomas; Nagy, Ferenc; Lonovics, Janos; Dignass, Axel; Landt, Olfert; Nickel, Renate; Genschel, Janine; Lochs, Herbert; Schmidt, Hartmut H.-J.; Witt, Heiko // American Journal of Gastroenterology;Apr2006, Vol. 101 Issue 4, p786 

    OBJECTIVES: Genetic variants within DLG5 were recently reported to be associated with inflammatory bowel disease (IBD). The aim of our study was to test for allelic and haplotype associations of six DLG5 variants in 668 IBD patients from two European populations. Furthermore, we evaluated...

  • Editorial: The Truth About Cigarette Smoking and the Risk of Inflammatory Bowel Disease. Rosenfeld, Greg; Bressler, Brian // American Journal of Gastroenterology;Sep2012, Vol. 107 Issue 9, p1407 

    Abstract: The etiology of inflammatory bowel disease (IBD) is generally believed to be multifactorial in nature involving both genetic and environmental factors. Cigarette smoking has been shown through previous retrospective observational studies to be an environmental factor with both positive...

  • Active and passive smoking behaviour and cessation plans of patients with Crohn's disease and ulcerative colitis van der Heide, Frans; Dijkstra, Arie; Albersnagel, Frans A.; Kleibeuker, Jan H.; Dijkstra, Gerard // Journal of Crohn's & Colitis;Jun2010, Vol. 4 Issue 2, p125 

    Abstract: Background: Smoking is a remarkable risk factor in inflammatory bowel disease (IBD), with negative effects on Crohn''s disease (CD) and positive effects on ulcerative colitis (UC). This makes different changes in smoking behaviour after diagnosis between CD and UC likely. Changes in...

  • Detection of DNA hypermethylation in sera of patients with Crohn's disease. JIN-HAN BAE; JONGHA PARK; KWANG MO YANG; TAE-OH KIM; JOO MI YI // Molecular Medicine Reports;2014, Vol. 9 Issue 2, p725 

    Mounting evidence suggests that inflammatory bowel disease (IBD) is caused by genetic predisposition of various genes as well as an abnormal interaction with environmental factors, resulting in epigenetic alterations. It has become evident that epigenetic factors play a significant contributory...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics